Zydus Cadila secures USFDA nod for Mesalamine ER Capsules

Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the United States Food & Drug Administration (USFDA) to market Mesalamine Extended-Release Capsules in the strength of 0.375 g, (US RLD: Apriso).

Mesalamine Extended-Release capsules are indicated for the maintenance of remission of ulcerative colitis in adults.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus Cadila ZyCoV-D likely to get emergency use nod this week: Sources